Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

CLICK HERE FOR CME CREDIT

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Stefano Del Prato, MD PhD

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism School of Medicine, University of Pisa Chief of the Section of Diabetes University of Pisa, Italy Clinical Associate Professor of Medicine University of Texas, San Antonio Health Science Center San Antonio, Texas